Biotech Values

[biomaven0]

CLDX PR:

Key quotes for this interim look:

In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed (CDX-011 ORR of 36%; IC ORR of 0%)

In patients with both triple negative breast cancer and high GPNMB expression, a statistically significant PFS benefit is currently observed (p=0.0032)

(Caution these subgroup numbers are very small).

Not slam-dunk results, but pretty intriguing - stock is down a bit AH so who knows what the market was hoping for.

http://ir.celldextherapeutics.com/phoenix.zhtml?c=93243&p=irol-newsArticle&ID=1699241&highlight=